| 1 |
NCT03472183 |
Recruiting |
Exploration of the Enteric Nervous System in Alzheimer Disease |
|
|
Interventional
|
Not Applicable |
- Nantes University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Differences in extracellular deposits of beta-amyloid peptide in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in tau protein in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in neuronal loss in enteric submucosal tissue between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease
- Differences in neuronal Glia cells in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
|
30 |
All |
50 Years to 80 Years (Adult, Older Adult) |
NCT03472183 |
RC17_0252 |
SYNEMA |
April 26, 2018 |
April 26, 2020 |
August 25, 2020 |
March 21, 2018 |
April 26, 2018 |
|
- Nantes university Hospital
Nantes, France
|
|
| 2 |
NCT01692977 |
Completed |
What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate? |
|
- Other: neuropsychological assessment
|
Interventional
|
Not Applicable |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Analyze nature and frequency of elements of the " art, memory and life " garden used as landmarks by Alzheimer's disease patients
- Study the characteristics of the elements that contributed to decision-making regarding spatial orientation, the cognitive map, correlations between success in experimental, neuropsychological assessment in Alzheimer disease and healthy control subjects.
|
77 |
All |
65 Years to 90 Years (Older Adult) |
NCT01692977 |
2011-A00993-38 |
JAZ-TOP |
August 2012 |
October 2014 |
October 2014 |
September 26, 2012 |
July 30, 2015 |
|
- University Hospital of Nancy , Saint Julien Hospital, France
Nancy, France
|
|
| 3 |
NCT03340571 |
Recruiting |
Blood Biomarker of Alzheimer's Disease (AD) |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Biological marker of Alzheimer's disease
|
60 |
All |
50 Years and older (Adult, Older Adult) |
NCT03340571 |
Pro00085997 |
|
March 12, 2018 |
August 2018 |
August 2018 |
November 13, 2017 |
March 14, 2018 |
|
- Duke University
Durham, North Carolina, United States
|
|
| 4 |
NCT02703636 |
Completed |
Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease |
- Mild to Moderate Alzheimer's Disease
|
|
Interventional
|
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE)
- Monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs).
- Change from baseline to Week 8 in Mini-Mental State Examination (MMSE) total score.
- (and 5 more...)
|
118 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT02703636 |
CENA713DJP02 |
ENA1stepswitch |
May 9, 2016 |
May 7, 2018 |
May 7, 2018 |
March 9, 2016 |
June 6, 2018 |
|
- Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan - Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan - Novartis Investigative Site
Tsukuba-city, Ibaraki, Japan - (and 16 more...)
|
|
| 5 |
NCT02672306 |
Active, not recruiting |
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease |
|
- Biological: UCMSCs
- Biological: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- South China Research Center for Stem Cell and Regenerative Medicine
- Guangzhou General Hospital of Guangzhou Military Command of PLA
- The Third Affiliated Hospital, SUN YAT-SEN University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
- Change in Mini-Mental State Examination (MMSE) Score
- Change in Clinician's Interview-Based Impression of Change (CIBIC-plus) Score
- (and 3 more...)
|
16 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT02672306 |
UCMSC-1 |
SEESUPAD |
October 20, 2017 |
October 2018 |
October 2019 |
February 3, 2016 |
April 26, 2018 |
|
- South China Research Center for Stem Cell and Regenerative Medicine,South China Institute of Biomedicine
Guangzhou, Guangdong, China
|
|
| 6 |
NCT03408041 |
Completed |
Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters |
|
- Other: Medical file data extraction
|
Observational
|
|
- Murielle Surquin
- Brugmann University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Age
- Sex
- Ethnic origin
- (and 2 more...)
|
129 |
All |
Child, Adult, Older Adult |
NCT03408041 |
CHUB-parameters Alzheimer |
|
May 1, 2016 |
October 1, 2017 |
October 1, 2017 |
January 23, 2018 |
January 23, 2018 |
|
- CHU Brugmann
Brussels, Belgium
|
|
| 7 |
NCT03255720 |
Not yet recruiting |
Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural Changes |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- the extent of tissue damage of several brain white matter regions in patients with Alzheimer's disease.
|
40 |
All |
60 Years to 80 Years (Adult, Older Adult) |
NCT03255720 |
diffusion tensor imaging |
|
September 29, 2017 |
December 1, 2022 |
December 31, 2022 |
August 21, 2017 |
September 26, 2017 |
|
|
|
| 8 |
NCT02349191 |
Not yet recruiting |
Omental Transposition Surgery for Mild Alzheimer's Disease |
|
- Procedure: Omental transposition for mild Alzheimers disease
|
Interventional
|
Not Applicable |
- Bariatric Medicine Institute, Salt Lake City, UT
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of surgical complications from beginning of anesthesia to discharge from Intensive Care Unit.
- Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 12 months.
- Change in Montreal Cognitive Assessment (MoCA) score from baseline at 12 months
- (and 6 more...)
|
25 |
All |
65 Years to 85 Years (Older Adult) |
NCT02349191 |
Cottam - 1 |
|
March 2016 |
April 2017 |
May 2019 |
January 28, 2015 |
March 22, 2016 |
|
|
|
| 9 |
NCT01796314 |
Completed |
Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life |
|
- Behavioral: Therapeutic Educational Program
|
Interventional
|
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Quality of life
- Caregiver quality of life
|
170 |
All |
50 Years to 100 Years (Adult, Older Adult) |
NCT01796314 |
RC31/11/255
PREQHOS n°11 255 07 |
THERAD |
January 2013 |
February 2017 |
February 2017 |
February 21, 2013 |
June 1, 2018 |
|
- CHU de Toulouse, Hôtel-Dieu, 2 rue Viguerie
Toulouse, France
|
|
| 10 |
NCT00987090 |
Unknown † |
Early-onset and Late-onset Sporadic Alzheimer's Disease (AD) |
|
- Biological: Clinic and neuropsychologic evaluation
- Radiation: MRI
- Procedure: PET
- (and 2 more...)
|
Interventional
|
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.
- to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.
|
240 |
All |
45 Years to 90 Years (Adult, Older Adult) |
NCT00987090 |
2008/24
2008-A01213-52 |
|
October 2009 |
September 2016 |
|
September 30, 2009 |
October 23, 2015 |
|
- Assistance Publique - Hôpitaux de Marseille
Marseille, France
|
|
| 11 |
NCT03090854 |
Not yet recruiting |
Cholinergic Markers Alzheimer's Disease |
|
|
Observational
|
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Neuropsychological test (ADASCog)
- Rate of responder AD in this cohort included according to the new AD criteria and comparison of the current rate with the previous rate published using former AD criteria
- Difference of CSF Ach AND AChE activity between responder and non responder groups
- Statistical evaluation of the link between CSF Ach, AChE activity, total and phosphorylated Tau, Aß40 and Aß42.
|
100 |
All |
50 Years and older (Adult, Older Adult) |
NCT03090854 |
K160402
2016-AO1639-42 |
CHOLINE |
September 1, 2017 |
September 1, 2019 |
September 1, 2019 |
March 27, 2017 |
August 29, 2017 |
|
- Centre Mémoire de Ressources et de Recherche Paris Nord
Paris, France
|
|
| 12 |
NCT01928420 |
Completed |
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease |
- Alzheimer's Disease
- Dementia
|
- Drug: Drug: NIC5-15
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Humanetics Corporation
- National Center for Complementary and Integrative Health (NCCIH)
- James J. Peters Veterans Affairs Medical Center
|
Industry / NIH / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
- Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score
- Change in Mini-Mental State Examination (MMSE) Score
- (and 4 more...)
|
30 |
All |
40 Years to 95 Years (Adult, Older Adult) |
NCT01928420 |
R21AT003302-01A1
MHBB-009-06S |
|
April 2007 |
June 2014 |
June 2014 |
August 26, 2013 |
October 17, 2016 |
|
- James J Peters Veterans Affairs Medical Center
Bronx, New York, United States
|
|
| 13 |
NCT03055741 |
Recruiting |
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil |
- Mild-moderate Alzheimer's Disease
|
- Drug: Donepezil
- Drug: DHP1401
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Daehwa Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale-cognition Korean version(ADAS-cog)
- Clinical Dementia Rating Sum of Box Korean version(CDR-SB)
- Neuropsychiatric Inventory-Q Korean version(NPI-Q)
- (and 3 more...)
|
180 |
All |
55 Years to 85 Years (Adult, Older Adult) |
NCT03055741 |
1401CS-2 |
|
December 28, 2016 |
September 2018 |
September 2018 |
February 16, 2017 |
December 4, 2017 |
|
- The Catholic University of Korea, Bucheon, ST. Mary's Hospital
Bucheon-si, Gyeonggi-do, Korea, Republic of - Myongji Hospital
Goyang-si, Gyeonggi-do, Korea, Republic of - Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of - (and 8 more...)
|
|
| 14 |
NCT00412048 |
Withdrawn |
Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease |
|
- Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
|
Interventional
|
Not Applicable |
- University Hospital, Strasbourg, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Comparing fMRI data between 3 groups of subjects: MCI, Alzheimer's disease and normal subjects
- Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer's disease
|
0 |
All |
55 Years to 75 Years (Adult, Older Adult) |
NCT00412048 |
3659 |
|
April 2012 |
February 2018 |
February 2018 |
December 15, 2006 |
November 14, 2012 |
|
|
|
| 15 |
NCT02253043 |
Recruiting |
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease |
|
- Device: Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)
|
Interventional
|
Not Applicable |
- Beijing Pins Medical Co., Ltd
- Beijing Tiantan Hospital
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog)
- Clinical Dementia Rating Scale
|
10 |
All |
40 Years to 80 Years (Adult, Older Adult) |
NCT02253043 |
PINS-002 |
|
May 2014 |
December 2018 |
December 2018 |
October 1, 2014 |
October 14, 2016 |
|
- Beijing Tiantan Hospital
Beijing, Beijing, China - 301 Hospatl
Beijing, Beijing, China
|
|
| 16 |
NCT01822951 |
Withdrawn |
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) |
|
- Drug: Cerebrolysin
- Drug: Donepezil
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in ADAS-cog. and CIBIC+ score distribution
- Adverse events
- Vital signs
- Laboratory tests
|
0 |
All |
50 Years and older (Adult, Older Adult) |
NCT01822951 |
EVE-AT-0412
2012-004944-31 |
DAT |
|
September 2016 |
December 2016 |
April 4, 2013 |
October 26, 2015 |
|
- AKh Allgemeines Krankenhaus der Stadt Linz GmbH
Linz, Austria
|
|
| 17 |
NCT02158910 |
Completed |
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients |
|
|
Observational
|
|
- Eisai Korea Inc.
- Eisai Inc.
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Safety and tolerability due to an increase of Aricept in patients with Alzheimer's disease.
|
2231 |
All |
Child, Adult, Older Adult |
NCT02158910 |
ART-M082-601 |
AID |
March 2015 |
June 2016 |
June 2016 |
June 9, 2014 |
March 7, 2017 |
|
- Busan, Korea, Republic of
- Chungcheongbuk-do, Korea, Republic of
- Chungcheongnam-do, Korea, Republic of
- (and 10 more...)
|
|
| 18 |
NCT02031198 |
Completed |
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease
- Immunogenicity of AADvac1
- Patient cognition
|
25 |
All |
50 Years to 86 Years (Adult, Older Adult) |
NCT02031198 |
AC-AD-002
2013-004499-36 |
FUNDAMANT |
January 2014 |
August 2016 |
December 2016 |
January 9, 2014 |
March 17, 2017 |
|
- Medizinische Universitat Graz
Graz, Steiermark, Austria - Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria - Medizinische Universitat Wien
Wien, Austria - Sozialmedizinisches Zentrum Ost (SMZ Ost) /Donauspital, Memory Clinic and Karl Landsteiner Institut for Amnestic disorders
Wien, Austria
|
|
| 19 |
NCT02565511 |
Recruiting |
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease |
|
- Biological: CAD106 Immunotherapy
- Other: Placebo to CAD106
- Drug: CNP520
- Other: Placebo to CNP520
|
Interventional
|
Phase 2
Phase 3 |
- Novartis Pharmaceuticals
- Banner Alzheimer's Institute
- National Institute on Aging (NIA)
- (and 3 more...)
|
Industry / Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease
- Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score
- Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score
- (and 7 more...)
|
1340 |
All |
60 Years to 75 Years (Adult, Older Adult) |
NCT02565511 |
CAPI015A2201J
2015-002715-15
1UF1AG046150-01 |
Generation S1 |
November 30, 2015 |
August 30, 2024 |
September 2, 2024 |
October 1, 2015 |
June 7, 2018 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States - Novartis Investigative Site
Phoenix, Arizona, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - (and 81 more...)
|
|
| 20 |
NCT00973518 |
Completed |
Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ consistently (e.g. at all evaluation time points) between HC and AD subjects
- Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ across time points within single subjects and across groups of HC and AD subjects
- Identification and characterization of Orasi SNI test features that correlate with independent measures of cognitive function based on functional testing (ADAS-Cog sum of boxes, and MMSE raw score, One Card Learning Test)
- (and 2 more...)
|
160 |
All |
50 Years to 90 Years (Adult, Older Adult) |
NCT00973518 |
ADD 09-02 |
|
September 2009 |
June 2010 |
June 2010 |
September 9, 2009 |
August 13, 2010 |
|
- Rush Alzheimer's Disease Center
Chicago, Illinois, United States - Alexian Brothers Neuroscience Institute
Elk Grove Village, Illinois, United States
|
|
| 21 |
NCT01609348 |
Completed
Has Results |
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3) |
- Alzheimer's Disease
- Depression
|
- Drug: Placebo
- Drug: Venlafaxine
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Changes in Dose Response Using the Modified Alzheimer's Disease (AD) Cooperative Study-Clinical Global Impression of Change.
|
5 |
All |
Child, Adult, Older Adult |
NCT01609348 |
NA_00066043 |
DIADs-3 |
April 2012 |
December 2016 |
January 2017 |
June 1, 2012 |
January 31, 2018 |
January 31, 2018 |
- Johns Hopkins at Bayview
Baltimore, Maryland, United States - Reading Hospital
West Reading, Pennsylvania, United States
|
|
| 22 |
NCT02947893 |
Recruiting |
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease |
|
- Drug: Placebo Capsule(s) Once a Day by Mouth
- Drug: Nilotinib Capsule(s) Once a Day by Mouth
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety will be measured by number of participants experiencing the occurrence of adverse events and/or abnormal laboratory values
- Effects of Nilotinib treatment on measurement of Nilotinib in the CSF
|
42 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT02947893 |
2016-0315 |
AD |
January 2017 |
February 2019 |
December 2019 |
October 28, 2016 |
February 20, 2018 |
|
- Georgetown University Medical Center
Washington, District of Columbia, United States
|
|
| 23 |
NCT02839187 |
Completed |
Neuro Imaging and Multimodal Alzheimer's Disease |
|
|
Interventional
|
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- fixing the AV-45 during PET
- Deposition of amyloid protein
- Standard Cognitive function
- Specific memory evaluation
|
59 |
All |
60 Years to 85 Years (Adult, Older Adult) |
NCT02839187 |
07 306 02 |
NIMAD |
June 2010 |
May 2012 |
May 2012 |
July 20, 2016 |
May 11, 2017 |
|
- University Hospital of Toulouse
Toulouse, France
|
|
| 24 |
NCT01850238 |
Completed |
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease |
|
- Biological: AADvac1
- Other: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease
- Immunogenicity of AADvac1
|
30 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT01850238 |
AXON CO 18700
2012-003916-29 |
|
May 2013 |
March 2015 |
March 2015 |
May 9, 2013 |
October 12, 2015 |
|
- Medizinische Universitat Graz
Graz, Steiermark, Austria - Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria - Medizinische Universitat Wien
Wien, Austria
|
|
| 25 |
NCT02195596 |
Unknown † |
Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study. |
|
- Other: High intensity aerobic exercise+strength
- Other: Low intensity aerobic exercise+strength
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Supportive Care
|
- Change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12
- Global cognitive performance
|
80 |
All |
55 Years to 85 Years (Adult, Older Adult) |
NCT02195596 |
2011111100 |
EFA-P |
April 2013 |
January 2015 |
December 2015 |
July 21, 2014 |
July 21, 2014 |
|
- Galdakao Hospital/Galdakao C.S.
Galdakao, Bilbao, Spain - Basauri C.S.
Basauri, Bizkaia, Spain - Hospital Universitario de Basurto
Bilbao, Bizkaia, Spain
|
|
| 26 |
NCT01311492 |
Completed |
Exercise Trial for Alzheimer's Disease |
|
- Behavioral: Healthy Lifestyle Program
- Behavioral: Physical Activity Intervention
|
Interventional
|
Not Applicable |
- Pennington Biomedical Research Center
- St. James Place of Baton Rouge
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Effect of exercise on cognitive decline
- Measuring the effects of exercise on depression, metabolic indices, and changes in overall function.
- Evidence based feasibility for conducting exercise interventions in the Alzheimer's Disease population.
|
10 |
All |
65 Years and older (Older Adult) |
NCT01311492 |
PBRC10035 |
EXTRA |
March 2011 |
April 2013 |
April 2013 |
March 9, 2011 |
May 27, 2013 |
|
- Programs of All-Inclusive Care for the Elderly (PACE)
Baton Rouge, Louisiana, United States - Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
|
|
| 27 |
NCT02769234 |
Enrolling by invitation |
EEG/ERP Longitudinal Study in Alzheimer's Disease (AD) |
|
- Procedure: ERP/EEG test
- Procedure: Psychometric testing
|
Observational
|
|
- Neuronetrix, Inc.
- Boston Center for Memory
- The Memory Clinic of Vermont
- Premiere Research Institute
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation (longitudinal change) between EEG/ERP vs. Neuropsychological Testing.
- Correlation (longitudinal change) between EEG/ERP vs ADNI-EF composite.
- Correlation (longitudinal change) between EEG/ERP vs. ADNI-Mem composite.
|
75 |
All |
60 Years to 95 Years (Adult, Older Adult) |
NCT02769234 |
SRP-1782 |
|
May 2016 |
June 2017 |
July 2017 |
May 11, 2016 |
May 30, 2017 |
|
- Premiere Research Institute
West Palm Beach, Florida, United States - Boston Center for Memory
Brookline, Massachusetts, United States - The Memory Clinic
Bennington, Vermont, United States
|
|
| 28 |
NCT02638519 |
Recruiting |
HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease |
|
- Other: Traditional Proton fMRI
- Other: Hyperpolarized Xenon-129 fMRI
- Drug: Hyperpolarized Xenon-129
- Device: 1H-129Xe Dual-Tuned Quadrature Head Coil
|
Interventional
|
Early Phase 1 |
- Thunder Bay Regional Research Institute
- Lakehead University
- Thunder Bay Regional Health Sciences Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Signal-to-Noise Ratio (SNR)
- P-Value
|
120 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02638519 |
RP-307-08312015 |
|
June 2016 |
June 2019 |
June 2019 |
December 23, 2015 |
November 17, 2017 |
|
- Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, Canada
|
|
| 29 |
NCT00818662 |
Completed
Has Results |
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease |
|
- Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg
- Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
- Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg
- Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
|
Interventional
|
Phase 3 |
- Baxalta now part of Shire
- Alzheimer's Disease Cooperative Study (ADCS)
- Shire
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)
- Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
- Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)
- (and 24 more...)
|
390 |
All |
50 Years to 89 Years (Adult, Older Adult) |
NCT00818662 |
160701 |
|
December 2008 |
December 2012 |
December 2012 |
January 8, 2009 |
November 24, 2017 |
October 28, 2014 |
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Sun City, Arizona, United States
- (and 38 more...)
|
|
| 30 |
NCT01409915 |
Active, not recruiting |
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease |
|
- Drug: Sagramostim
- Drug: Saline -- placebo comparator
|
Interventional
|
Phase 2 |
- University of Colorado, Denver
- The Dana Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Ability of Alzheimer's Disease subjects to tolerate Leukine treatment will be assessed
- Ability of Leukine treatment to improve cognition of Alzheimer's Disease subjects
|
40 |
All |
55 Years to 85 Years (Adult, Older Adult) |
NCT01409915 |
12-1273 |
|
March 2011 |
November 2018 |
November 2018 |
August 4, 2011 |
January 18, 2018 |
|
- University of Colorado Denver, Anschutz Medical Campus
Aurora, Colorado, United States
|
|
| 31 |
NCT03373604 |
Enrolling by invitation |
Imaging Tau in Alzheimer's Disease and Normal Aging |
|
- Drug: 18F-MK-6240
- Procedure: Lumbar Puncture (optional)
|
Interventional
|
Phase 2 |
- William Charles Kreisl
- National Institute on Aging (NIA)
- Columbia University
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- 18F-MK-6240 binding (standardized uptake value ratio)
- Correlation of 18F-MK-6240 binding and CSF markers of neurodegeneration and inflammation.
|
175 |
All |
50 Years to 100 Years (Adult, Older Adult) |
NCT03373604 |
AAAR4352
K23AG052633-02
2R56AG034189-06A1
K24AG045334
R01AG055299
R01AG050440-02S1 |
|
December 11, 2017 |
August 20, 2021 |
August 20, 2021 |
December 14, 2017 |
June 7, 2018 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 32 |
NCT02925650 |
Recruiting |
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease |
|
- Drug: Posiphen
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- QR Pharma Inc.
- Alzheimer's Disease Cooperative Study (ADCS)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety and Tolerability: Reports of adverse events or study discontinuations
- AUC of Posiphen and its metabolites in plasma and CSF
- Fractional synthesis rate of Aβ40 in CSF using the SILK™ technique
- (and 4 more...)
|
24 |
All |
55 Years to 85 Years (Adult, Older Adult) |
NCT02925650 |
QR15001
ADC-042-DISC |
DISCOVER |
March 2, 2017 |
December 31, 2019 |
December 31, 2019 |
October 6, 2016 |
April 4, 2018 |
|
- UCSD Alzheimer's Disease Research Center
La Jolla, California, United States - IU Health Partners, Adult Neurology Clinic
Indianapolis, Indiana, United States - Johns Hopkins Hospital
Baltimore, Maryland, United States - Washington University Sleep Medicine Center
Brentwood, Missouri, United States
|
|
| 33 |
NCT03507257 |
Recruiting |
Longitudinal Early-onset Alzheimer's Disease Study Protocol |
- Early Onset Alzheimer Disease
- Alzheimer Disease
- Mild Cognitive Impairment
|
- Drug: Flortaucipir
- Drug: Florbetaben
|
Observational
|
|
- Liana Apostolova
- Alzheimer's Therapeutic Research Institute
- National Institute on Aging (NIA)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of change in cognition as measured by by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)
- Rate of change in cognition as measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB)
- Rate of change in cognition as measured by the Clinician Judgment of Symptoms form from the NACC UDS.
- (and 5 more...)
|
500 |
All |
40 Years to 64 Years (Adult) |
NCT03507257 |
ATRI-003
R56AG057195 |
LEADS |
April 30, 2018 |
August 31, 2022 |
August 31, 2023 |
April 25, 2018 |
June 5, 2018 |
|
- Indiana University
Bloomington, Indiana, United States
|
|
| 34 |
NCT02959489 |
Recruiting |
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN) |
- Alzheimer Disease
- Amyloid Beta-Peptides
- Risk Assessment
- (and 3 more...)
|
- Behavioral: Alzheimer's Disease Risk Disclosure
- Behavioral: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
|
Interventional
|
Not Applicable |
- Brigham and Women's Hospital
- University of Pennsylvania
- University of Michigan
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Change in baseline neuropsychological performance compared to 6 weeks and 6 months post-disclosure
- Change in baseline measure scores on scales and questionnaires of psychological distress compared to 6 weeks and 6 months post-disclosure.
- Change in baseline measures of health behaviors compared to 6 weeks and 6 months post-disclosure to determine the type and frequency of behavior changes in response to learning risk information.
|
270 |
All |
65 Years to 80 Years (Older Adult) |
NCT02959489 |
RF1AG047866
1RF1AG047866-01A1 |
REVEAL-SCAN |
November 2016 |
July 2019 |
July 2019 |
November 9, 2016 |
December 20, 2016 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - University of Michigan
Ann Arbor, Michigan, United States - Duke University
Durham, North Carolina, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
|
| 35 |
NCT02899091 |
Not yet recruiting |
Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease |
|
- Biological: CB-AC-02
- Biological: Placebo
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of Adverse Events
- Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score
- Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score
- (and 11 more...)
|
24 |
All |
50 Years and older (Adult, Older Adult) |
NCT02899091 |
CHA-PAD-101 |
|
September 2016 |
March 2018 |
June 2018 |
September 14, 2016 |
September 14, 2016 |
|
- Bundang Medical Center
Seongnam-si, Gyeonggi-do, Korea, Republic of
|
|
| 36 |
NCT01399125 |
Completed
Has Results |
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease |
|
- Drug: Rivastigmine Patch
- Drug: Rivastigmine Capsules
- Drug: Placebo to Rivastigmine patch
- Drug: Placebo to Rivastigmine capsules
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline on Cognition, Assessed by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)
- Change From Baseline in Global Functioning, Assessed by the Alzheimer's Disease Assessment Scale Clinical Impression of Change (ADCS-CGIC)
- Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Total Score
- (and 2 more...)
|
501 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT01399125 |
CENA713D2344 |
|
July 2011 |
May 2013 |
May 2013 |
July 21, 2011 |
August 4, 2014 |
August 4, 2014 |
- Novartis Investigative Site
Fuzhou, Fujian, China - Novartis Investigative Site
Wuhan, Hubei, China - Novartis Investigative Site
Wuhan, Hubei, China - (and 13 more...)
|
|
| 37 |
NCT03136679 |
Recruiting |
Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease |
- Mild Cognitive Impairment
- Alzheimer Disease
|
|
Observational
|
|
- Baylor Research Institute
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Discovery of novel biomarkers that will lead to the early detection of Alzheimer's disease.
|
220 |
All |
40 Years and older (Adult, Older Adult) |
NCT03136679 |
017-039 |
BVB |
March 22, 2017 |
April 30, 2019 |
December 31, 2019 |
May 2, 2017 |
May 4, 2017 |
|
- Baylor AT&T Memory Center
Dallas, Texas, United States
|
|
| 38 |
NCT02377206 |
Unknown † |
Neuroinflammation and Cognitive Decline in Alzheimer Disease |
|
- Other: ADAS-Cog evaluation
|
Interventional
|
Phase 1 |
- University Hospital, Tours
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change from baseline in ADAS-Cog score
- Quantification of neuroinflammation by [18F]DPA-714 PET imaging
|
45 |
All |
60 Years to 85 Years (Adult, Older Adult) |
NCT02377206 |
PRTS13-CH / NICAD |
NICAD |
March 2015 |
March 2017 |
March 2017 |
March 3, 2015 |
June 23, 2015 |
|
- University hospital of Caen
Caen, France - university hospital of Nantes
Nantes, France - University Hospital of Rennes
Rennes, France - University Hospital of Tours
Tours, France
|
|
| 39 |
NCT01529619 |
Completed |
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors |
|
- Drug: Rivastigmine transdermal patch
|
Interventional
|
Phase 4 |
- Novartis Pharmaceuticals
- Ono Pharmaceutical Co. Ltd
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J cog)
- Adverse Events, Serious Adverse Events, Adverse event leading to discontinuation of study drug
- Change From Baseline in Disability Assessment for Dementia (DAD)
- (and 4 more...)
|
52 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT01529619 |
CENA713D1403 |
|
March 2012 |
December 2013 |
December 2013 |
February 9, 2012 |
November 18, 2016 |
|
- Novartis Investigative Site
Nagoya-city, Aichi, Japan - Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan - Novartis Investigative Site
Miyoshi-city, Hiroshima, Japan - (and 8 more...)
|
|
| 40 |
NCT00876863 |
Active, not recruiting |
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease |
|
- Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF
- Procedure: Placebo Surgery
|
Interventional
|
Phase 2 |
- Sangamo Therapeutics
- Alzheimer's Disease Cooperative Study (ADCS)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
- Neuropsychological Test Battery
- Mini-Mental State Examination (MMSE)
- (and 2 more...)
|
50 |
All |
55 Years to 80 Years (Adult, Older Adult) |
NCT00876863 |
CERE-110-03
NIH Grant 1R01AG030048-01A1 |
|
September 2009 |
December 2019 |
March 2020 |
April 7, 2009 |
January 10, 2017 |
|
- University of Alabama
Birmingham, Alabama, United States - University of California, Los Angeles
Los Angeles, California, United States - University of California, San Diego
San Diego, California, United States - (and 7 more...)
|
|
| 41 |
NCT01993836 |
Recruiting |
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care |
- Alzheimers Disease
- Postoperative Delirium
- Post Operative Cognitive Dysfunction
|
- Drug: Total intravenous anesthesia with propofol
- Drug: General anesthesia with isoflurane
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Assess the correlation between perioperative change in CSF Markers of Alzheimers Disease and perioperative cognitive change.
- Continuous cognitive index score change
- Assess CSF Markers of Alzheimers Disease
- Perioperative CSF Tau/Abeta ratio change
|
140 |
All |
60 Years and older (Adult, Older Adult) |
NCT01993836 |
Pro00045180 |
MADCO-PC |
November 2013 |
February 2019 |
February 2019 |
November 25, 2013 |
January 19, 2018 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
|
| 42 |
NCT03282916 |
Recruiting |
Anti-viral Therapy in Alzheimer's Disease |
- Alzheimer Disease
- Herpes Simplex 1
- Herpes Simplex 2
|
- Drug: Valacyclovir
- Drug: Placebo
|
Interventional
|
Phase 2 |
- New York State Psychiatric Institute
- National Institutes of Health (NIH)
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-COG11, modified version) scores from baseline to 78 weeks.
- Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scores from baseline to 78 weeks.
- Change in total 18F-Florbetapir brain uptake from baseline to 78 weeks.
|
130 |
All |
55 Years to 95 Years (Adult, Older Adult) |
NCT03282916 |
7537
R01AG055422 |
|
February 12, 2018 |
August 2022 |
August 2022 |
September 14, 2017 |
June 13, 2018 |
|
- New York State Psychiatric Institute
New York, New York, United States
|
|
| 43 |
NCT02208193 |
Unknown † |
Alzheimer's Disease, Art and Garden |
|
- Behavioral: Cognitive and psycho-behavioral effects of an artistic dimension
|
Interventional
|
Not Applicable |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Comparaison of the number of language acts in each category between AD and controls subjects
- Scores obtained in standard neuropsychological tests, in particular to assess spatio-temporal orientation (Folstein MMSE),
- Scores obtained with the " MemoArtZ " tool (MAZ) to evaluate the memorization of artistic elements of the garden,
- (and 3 more...)
|
60 |
All |
60 Years and older (Adult, Older Adult) |
NCT02208193 |
2014-A00139-38 |
JAZ ART |
July 2014 |
October 2016 |
September 2017 |
August 4, 2014 |
July 30, 2015 |
|
|
|
| 44 |
NCT02537496 |
Recruiting |
Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS |
|
- Procedure: Repetitive Transcranial Magnetic Stimulation
- Procedure: Repetitive Transcranial Magnetic Stimulation - Sham
|
Interventional
|
Not Applicable |
- Centre for Addiction and Mental Health
- Brain & Behavior Research Foundation
- University of Toronto
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in N-back Task Performance
- Changes in Theta Phase-Gamma Amplitude Coupling
- Changes in DLPFC Neuroplasticity
- (and 2 more...)
|
36 |
All |
55 Years and older (Adult, Older Adult) |
NCT02537496 |
005/2015 |
rTMS-AD |
August 2015 |
August 2018 |
August 2018 |
September 1, 2015 |
January 23, 2018 |
|
- Center for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 45 |
NCT01864655 |
Completed |
Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease |
|
- Drug: saracatinib
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Stephen M. Strittmatter
- Yale University
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events on AZD0530
- CNS availability of AZD0530 after oral dosing
- Effects of AZD0530 on cognitive function in patients with Alzheimer's disease
- Effect of AZD0530 on brain glucose metabolism in patients with Alzheimer's disease
|
24 |
All |
50 Years to 90 Years (Adult, Older Adult) |
NCT01864655 |
1UH2TR000967-01 |
|
July 2013 |
March 2014 |
|
May 29, 2013 |
June 13, 2014 |
|
- Yale Alzheimer's Disease Research Unit
New Haven, Connecticut, United States
|
|
| 46 |
NCT02017340 |
Completed |
A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease |
|
- Drug: Nilvadipine
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Prof Brian Lawlor
- University of Dublin, Trinity College
- Molecular Medicine Ireland LBG
- (and 14 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale (ADAS) Cog
- Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)
- Disability Assessment for Dementia (DAD)
|
511 |
All |
50 Years and older (Adult, Older Adult) |
NCT02017340 |
NILVAD2012
2012-002764-27
279093 |
NILVAD |
April 24, 2013 |
December 16, 2016 |
December 16, 2016 |
December 20, 2013 |
March 6, 2017 |
|
- Centre Hospitalier Universitaire d'Amiens (CHU Amiens)
Amiens, France - Centre Hospitalier Universitaire de Bethune (CH Bethune)
Bethune, France - Centre Hospitalier Universitaire de Caen (CHU Caen)
Caen, France - (and 20 more...)
|
|
| 47 |
NCT01028053 |
Completed
Has Results |
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease |
- Mild Cognitive Impairment
- Alzheimer's Disease
|
- Drug: Flutemetamol (18F) Injection
|
Interventional
|
Phase 3 |
- GE Healthcare
- Medpace, Inc.
- i3 Statprobe
- (and 2 more...)
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.
- The of Normal and Abnormal Subjects Who Convert to Probable Alzheimer's Disease (pAD) Within the Follow up Period.
|
365 |
All |
60 Years and older (Adult, Older Adult) |
NCT01028053 |
GE-067-005 |
|
December 2009 |
January 2014 |
January 2014 |
December 9, 2009 |
September 11, 2014 |
September 11, 2014 |
- GE Healthcare
Princeton, New Jersey, United States
|
|
| 48 |
NCT00945672 |
Completed |
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease |
|
- Biological: PF-04360365 10 mg/kg
- Biological: PF-04360365 7.5 mg/kg
- Drug: placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Safety/tolerability/PK of multiple doses of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 1 year (adverse events, physical/neurological exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)
- Brain amyloid burden
- CSF abeta
- Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma abeta, CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; immunogenicity (anti-drug antibodies)
|
36 |
All |
50 Years and older (Adult, Older Adult) |
NCT00945672 |
A9951007 |
|
August 2009 |
June 2011 |
June 2011 |
July 24, 2009 |
May 5, 2016 |
|
- Pfizer Investigational Site
Göteborg, Sweden - Pfizer Investigational Site
Malmo, Sweden - Pfizer Investigational Site
Molndal, Sweden - Pfizer Investigational Site
Stockholm, Sweden
|
|
| 49 |
NCT02884492 |
Completed |
Imaging Tau in Alzheimer's Disease and Normal Aging |
|
- Drug: 18F-THK-5351
- Procedure: Lumbar Puncture (optional)
|
Interventional
|
Phase 2 |
- William Charles Kreisl
- National Institute on Aging (NIA)
- Columbia University
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Change in 18F-THK-5351 uptake value ratio
- Change in CSF concentration of inflammatory markers
- Change in CSF concentration of β-amyloid , tau and phospho-tau
|
17 |
All |
50 Years and older (Adult, Older Adult) |
NCT02884492 |
AAAQ7868
1K23AG052633-01 |
|
July 2016 |
June 2017 |
June 2017 |
August 31, 2016 |
May 16, 2018 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 50 |
NCT02501876 |
Completed |
Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease |
- Alzheimer´s Disease
- Diabetes Mellitus Type 2
|
- Other: There is a retrospectiv observational study. No intervention
|
Observational
|
|
- Hospital Universitari Vall d'Hebron Research Institute
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
- The rate of conversion to Alzheimer's disease (AD)
- The presence of common alleles for Alzheimer's disease (AD) and Diabetes mellitus type 2
|
202 |
All |
65 Years to 90 Years (Older Adult) |
NCT02501876 |
PR(AG)32/2015 |
DIACEA |
May 2015 |
September 2015 |
May 2016 |
July 17, 2015 |
April 12, 2017 |
|
- Vall d´Hebron University Hospital
Barcelona, Spain
|
|
Create an RSS feed from your search for:
Download the search results for: